Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 195

Similar articles for PubMed (Select 1532962)

1.

Pharmacotherapy of obsessive compulsive disorder.

Goodman WK, McDougle CJ, Price LH.

J Clin Psychiatry. 1992 Apr;53 Suppl:29-37. Review.

PMID:
1532962
2.

Electroconvulsive therapy for obsessive-compulsive disorder: a systematic review.

Fontenelle LF, Coutinho ES, Lins-Martins NM, Fitzgerald PB, Fujiwara H, Yücel M.

J Clin Psychiatry. 2015 Mar 3. [Epub ahead of print]

PMID:
25844888
3.

The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: Views based on a systematic review and meta-analysis.

Ivarsson T, Skarphedinsson G, Kornør H, Axelsdottir B, Biedilæ S, Heyman I, Asbahr F, Thomsen PH, Fineberg N, March J; Accreditation Task Force of The Canadian Institute for Obsessive Compulsive Disorders.

Psychiatry Res. 2015 May 30;227(1):93-103. doi: 10.1016/j.psychres.2015.01.015. Epub 2015 Jan 28. Review.

PMID:
25769521
4.

Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.

Zai G, Brandl EJ, Müller DJ, Richter MA, Kennedy JL.

Pharmacogenomics. 2014 Jun;15(8):1147-57. doi: 10.2217/pgs.14.83. Review. Erratum in: Pharmacogenomics. 2015;16(6):668.

PMID:
25084207
5.

Rapid, illegible handwriting as a symptom of obsessive-compulsive disorder.

Bavle A, Andrade C, Vidhyavathi M.

Indian J Psychiatry. 2014 Apr;56(2):200-1. doi: 10.4103/0019-5545.130511.

6.

An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder.

Pizarro M, Fontenelle LF, Paravidino DC, Yücel M, Miguel EC, de Menezes GB.

Expert Opin Pharmacother. 2014 Jul;15(10):1391-401. doi: 10.1517/14656566.2014.914493. Epub 2014 Apr 28. Review.

PMID:
24766145
7.

Khedzela--a new brand of desvenlafaxine.

[No authors listed]

Med Lett Drugs Ther. 2014 Jan 6;56(1433):4. No abstract available.

PMID:
24419297
8.

Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder.

Arrojo-Romero M, Tajes Alonso M, de Leon J.

Case Rep Psychiatry. 2013;2013:612459. doi: 10.1155/2013/612459. Epub 2013 Jul 14.

9.

Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder.

Kreiss DS, Coffman CF, Fiacco NR, Granger JC, Helton BM, Jackson JC, Kim LV, Mistry RS, Mizer TM, Palmer LV, Vacca JA, Winkler SS, Zimmer BA.

Pharmacol Biochem Behav. 2013 Mar;104:119-24. doi: 10.1016/j.pbb.2013.01.006. Epub 2013 Jan 17.

PMID:
23333679
10.

Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.

Fineberg NA, Reghunandanan S, Brown A, Pampaloni I.

Aust N Z J Psychiatry. 2013 Feb;47(2):121-41. doi: 10.1177/0004867412461958. Epub 2012 Nov 2. Review.

PMID:
23125399
11.

Selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder in children and adolescents.

Williams JS, Moore T, Collins CL, Thomas KA.

J Pediatr Pharmacol Ther. 2003 Jul;8(3):177-86. doi: 10.5863/1551-6776-8.3.177.

12.

[Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].

Nakamae T.

Seishin Shinkeigaku Zasshi. 2011;113(10):1016-25. Review. Japanese.

PMID:
22187889
13.

Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice.

Shanahan NA, Velez LP, Masten VL, Dulawa SC.

Biol Psychiatry. 2011 Dec 1;70(11):1039-48. doi: 10.1016/j.biopsych.2011.07.032. Epub 2011 Sep 13.

14.

Efficacy of antidepressant medications in children and adolescents with obsessive-compulsive disorder: a systematic appraisal.

Gentile S.

J Clin Psychopharmacol. 2011 Oct;31(5):625-32. doi: 10.1097/JCP.0b013e31822bb1ff. Review.

PMID:
21869690
15.

SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder?

Sansone RA, Sansone LA.

Innov Clin Neurosci. 2011 Jun;8(6):10-4.

16.

[Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].

Okamoto Y.

Seishin Shinkeigaku Zasshi. 2011;113(1):36-44. Japanese.

PMID:
21404630
17.

Clinical treatment of obsessive compulsive disorder.

Pittenger C, Kelmendi B, Bloch M, Krystal JH, Coric V.

Psychiatry (Edgmont). 2005 Nov;2(11):34-43.

18.

[Torin (sertraline) in the treatment of depressive and obsessive-compulsive disorders in children].

Malinina EV, Zabozlaeva IV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(8):22-4. Russian.

PMID:
20823825
19.

Past, present and future drugs for the treatment of obsessive-compulsive disorder.

Marazziti D, Consoli G, Baroni S, Catena Dell'Osso M.

Curr Med Chem. 2010;17(29):3410-21. Review.

PMID:
20712565
20.

No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression.

Maina G, Rosso G, Rigardetto S, Chiadò Piat S, Bogetto F.

Psychother Psychosom. 2010;79(5):295-302. doi: 10.1159/000318296. Epub 2010 Jul 9.

PMID:
20616624
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk